# US 2020/0005894 A1 · Method and system for sample identity assurance

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0005894 A1
- Document ID: US20200005894A1
- Status: Published application
- Kind: A1
- Application number: 16/457,215
- Filed: 2019-06-28
- Published: 2020-01-02
- Earliest claimed: 2018-06-29
- Assignees: Rady Children's Hospital Research Center
- Applicants: Rady Children's Hospital Research Center
- Inventors: Yan Ding; Sergey Batalov
- Web page: https://patentgrep.com/patent/US20200005894A1

## CPC

- G16B 30/00: ICT specially adapted for sequence analysis involving nucleotides or amino acids
- C12Q 1/6827: for detection of mutation or polymorphism
- C12Q 1/6869: Methods for sequencing
- C12Q 1/6876: Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- G16B 20/20: Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
- G16B 40/10: Signal processing, e.g. from mass spectrometry [MS] or from PCR
- C12Q 2600/156: Polymorphic or mutational markers
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present disclosure provides a method for genetic analysis including allelotyping as well as a system for implementing such analysis.

## Claims

### Claim 1

A method comprising:
a) determining a first allelotype for a sample via short tandem repeat (STR) amplification;
b) determining a second allelotype for the sample via genetic sequencing; and
c) determining allele concordance between the first allelotype and the second allelotype.

### Claim 2 (depends on 1)

The method of claim 1, wherein (c) comprises generating an allele profiling concordance table.

### Claim 3 (depends on 1)

The method of claim 1, further comprising calculating a statistical probability to determine whether the first allelotype and the second allelotype are of a single subject.

### Claim 4 (depends on 3)

The method of claim 3, wherein the subject is human.

### Claim 5 (depends on 1)

The method of claim 1, wherein the first allelotype is generated via GeneMapper™.

### Claim 6 (depends on 1)

The method of claim 1, wherein the second allelotype is generated via lobSTR™.

### Claim 7 (depends on 1)

The method of claim 1, wherein the sample is a biological sample.

### Claim 8 (depends on 1)

The method of claim 1, wherein the sample is whole blood, plasma, serum, ascites, cerebrospinal fluid, sweat, urine, tears, saliva, buccal sample, cavity rinse, feces, organ rinse, hair or skin.

### Claim 9 (depends on 1)

The method of claim 1, wherein the sample is blood.

### Claim 10 (depends on 1)

The method of claim 1, wherein genetic sequencing comprises whole genome sequencing (WGS), rapid whole genome sequencing (rWGS), whole exome sequencing (WES), next-generation sequence (NGS), targeted gene panel sequencing, or a combination thereof.

### Claim 11 (depends on 10)

The method of claim 10, wherein WES or targeted gene panel sequencing comprises a panel having one or more oligonucleotides selected from the group consisting of SEQ ID NOs: 1-41.

### Claim 12 (depends on 11)

The method of claim 11, wherein each oligonucleotide is between about 50 to 120 nucleotides in length.

### Claim 13 (depends on 11)

The method of claim 11, wherein each oligonucleotide is 50 nucleotides in length or greater.

### Claim 14 (depends on 11)

The method of claim 11, wherein each oligonucleotide is 120 nucleotides in length or less.

### Claim 15 (depends on 1)

The method of claim 1, wherein (a) and (b) are performed in parallel.

### Claim 16

A panel comprising one or more oligonucleotides selected from the group consisting of SEQ ID NOs: 1-41.

### Claim 17 (depends on 16)

The panel of claim 16, wherein each oligonucleotide is between about 50 to 120 nucleotides in length.

### Claim 18 (depends on 16)

The panel of claim 16, wherein each oligonucleotide is 50 nucleotides in length or greater.

### Claim 19 (depends on 16)

The panel of claim 16, wherein each oligonucleotide is 120 nucleotides in length or less.

### Claim 20

A genetic analysis system comprising: a) at least one processor operatively connected to a memory; b) a receiver component configured to receive DNA analysis information including sequence information generated from PCR amplification of DNA in a DNA sample; and c) an analysis component, executed by the at least one processor, configured to determine: i) an allelotype from the sequence information; ii) generate an allele profiling concordance table; and iii) calculate a statistical probability to determine whether a first allelotype and a second allelotype are from a single subject.

### Claim 21 (depends on 1)

A genetic analysis system comprising: a) at least one processor operatively connected to a memory; b) a receiver component configured to receive DNA analysis information including sequence information generated from PCR amplification of DNA in a DNA sample; and c) an analysis component, executed by the at least one processor, configured to perform (a)-(c) of claim 1.
